Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer
|ClinicalTrials.gov Identifier: NCT00899132|
Recruitment Status : Terminated (Study due for continuing review)
First Posted : May 12, 2009
Last Update Posted : September 29, 2015
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is evaluating a tumor marker for testicular cancer, skin cancer, small intestine cancer, and pancreatic cancer.
|Condition or disease||Intervention/treatment|
|Non-melanomatous Skin Cancer Pancreatic Cancer Small Intestine Cancer Testicular Germ Cell Tumor||Genetic: in situ hybridization Genetic: protein expression analysis Other: immunologic technique|
- To identify TAB3 transcript/protein as a molecular marker of cancer, specifically testicular, skin, small intestine, and pancreatic cancer.
- To characterize TAB3 and its signaling networks that are involved in tumorigenesis.
OUTLINE: Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
|Study Type :||Observational|
|Actual Enrollment :||180 participants|
|Official Title:||The Role of TAB3 Protein in Tumorigenesis|
|Study Start Date :||February 2007|
|Primary Completion Date :||September 2012|
|Study Completion Date :||September 2012|
Genetic: in situ hybridization
- Identification of TAB3 transcript/protein as a molecular marker of cancer [ Time Frame: end of study ]
- Characterization of TAB3 and its signaling networks that are involved in tumorigenesis [ Time Frame: end of study ]
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00899132
|United States, Ohio|
|Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center|
|Cleveland, Ohio, United States, 44106-5065|
|Study Chair:||Ge Jin, PhD||Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center|